Investor Contact:Paul Cox, Sage Therapeuticspaul.firstname.lastname@example.orgMedia Contact:Dan Budwick, Pure Communicationsdan@purecommunicationsinc.com973-271-6085
CAMBRIDGE, Mass., Jan. 04, 2016 (GLOBE NEWSWIRE) -- Sage Therapeutics (NASDAQ:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that Jeff Jonas, M.D., Chief Executive Officer of SAGE, will provide a corporate presentation at the 34 th Annual J.P. Morgan Healthcare Conference at 11:30 a.m. PT (2:30 p.m. ET) on Monday, January 11, 2016, in San Francisco. A live webcast of the presentation can be accessed on the investor page of SAGE's website at investor.sagerx.com. A replay of the webcast will also be archived for up to 30 days on SAGE's website following the conference. About Sage Therapeutics Sage Therapeutics (NASDAQ:SAGE) is a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders. SAGE has a portfolio of novel product candidates targeting critical CNS receptor systems, GABA and NMDA. SAGE's lead program, SAGE-547, is in Phase 3 clinical development for super-refractory status epilepticus, a rare and severe seizure disorder. SAGE is developing its next generation modulators, including SAGE-217 and SAGE-689, with a focus on acute and chronic CNS disorders. For more information, please visit www.sagerx.com.